EGFR and colorectal carcinoma: Therefore, to improve the efficacy of MRTX849 in CRC, trials of its combination of cetuximab (an anti-EGFR antibody) and TNO155 (an SHP2 inhibitor) are underway, but the results have not been published (NCT04793958, NCT04330664; Table 3).